Skip to main content

Table 1 Subject Demographics and Baseline Characteristics

From: Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma

Demographic or Characteristic

MF/F-MDI

200/10 μg BID (n = 371)

FP/S-DPI

250/50 μg BID (n = 351)

Sex, n (%)

  

   Female

239 (64)

220 (63)

Race, n (%)

  

   White

323 (87)

301 (86)

Mean age, y (range)

44.8 (12-82)

45.1 (12-80)

Duration of asthma, y

  

   Mean

15.0

15.9

   Median

11.0

13.0

Prior ICS use, n (%)*

225 (61)

188 (54)

Prior ICS/LABA use, n (%)*

  

   Budesonide/formoterol

59 (16)

59 (17)

   Fluticasone/salmeterol

104 (28)

115 (33)

Mean FEV1 at baseline

  

   L

2.30

2.37

   Percentage predicted

73.8

74.4

Mean total ACQ score

1.80

1.80

Mean total AQLQ(S) score

5.14

5.14

  1. ACQ = Asthma Control Questionnaire; AQLQ(S) = Asthma Quality of Life Questionnaire With Standardized Activities; BID = twice daily; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 s; FP/S = fluticasone propionate/salmeterol; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol.
  2. *Subjects could have received multiple types of ICS monotherapy and combination ICS/LABA therapy in the 3 months before screening.
  3. ACQ score based on a 7-point scale that ranged from 0 (best asthma control) to 6 (worst asthma control).
  4. AQLQ(S) score based on a 7-point scale that ranged from 1 (worst quality of life) to 7 (best quality of life)